# 2nd International Symposium on Merkel Cell Carcinoma

## MJ2207 - 2nd International Symposium on Merkel Cell Carcinoma

### Overview

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monday, April 25</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>April 25-26, 2022</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Registration &amp; Breakfast</td>
<td>7:00AM - 7:35AM</td>
<td></td>
</tr>
<tr>
<td>Welcome Remarks &amp; Course Intro</td>
<td>7:35AM - 7:40AM</td>
<td>Paul Nghiem, MD, PhD (Course Co-Chair)</td>
</tr>
<tr>
<td>CME Knowledge Assessment (ARS)</td>
<td>7:40AM - 7:45AM</td>
<td></td>
</tr>
<tr>
<td>State of the Field: Merkel Cell Carcinoma</td>
<td>7:45AM - 8:00AM</td>
<td>Paul Nghiem, MD, PhD</td>
</tr>
<tr>
<td><strong>1. MCC Biology I</strong></td>
<td>8:00AM - 9:40AM</td>
<td></td>
</tr>
<tr>
<td>Immunotherapy Platform and Related-omics</td>
<td>8:00AM - 8:20AM</td>
<td>Kenneth Tsai, MD, PhD</td>
</tr>
<tr>
<td>Animal Models of MCC</td>
<td>8:20AM - 8:40AM</td>
<td>Andrezj Dlugosz, MD</td>
</tr>
<tr>
<td>Mechanisms of Oncogenesis: MCC Cell of Origin</td>
<td>8:40AM - 9:00AM</td>
<td>Jurgen Becker, MD, PhD</td>
</tr>
<tr>
<td>Clues to the Origins of Merkel Cell Carcinoma</td>
<td>9:00AM - 9:20AM</td>
<td>Paul Harris, MD, PhD</td>
</tr>
<tr>
<td>Epigenetic and Genetic Determinants of Merkel Cell Carcinoma</td>
<td>9:20AM - 9:40AM</td>
<td>Isaac Brownell, MD, PhD</td>
</tr>
<tr>
<td><strong>BREAK</strong></td>
<td>9:40AM - 10:00AM</td>
<td></td>
</tr>
<tr>
<td><strong>2. Treatment</strong></td>
<td>10:00AM - 12:00PM</td>
<td></td>
</tr>
<tr>
<td>Surgery - Adjuvant RT</td>
<td>10:00AM - 10:20AM</td>
<td>Alexander van Akkooi, MD, PhD</td>
</tr>
<tr>
<td>Role of radiotherapy in Merkel cell cancer</td>
<td>10:20AM - 10:40AM</td>
<td></td>
</tr>
<tr>
<td>Systemic therapies for metastatic Merkel cell carcinoma</td>
<td>10:40AM - 11:00AM</td>
<td></td>
</tr>
<tr>
<td>Neoadjuvant PD-1 Pathway Blockade for MCC: a window into treatment response and primary resistance</td>
<td>11:00AM - 11:20AM</td>
<td></td>
</tr>
</tbody>
</table>

**Tuesday, April 26, 2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00AM - 7:45AM</td>
<td>Sign In &amp; Breakfast</td>
</tr>
<tr>
<td>7:45AM - 7:50AM</td>
<td>Welcome Remarks &amp; Course Intro</td>
</tr>
<tr>
<td>7:50AM - 8:00AM</td>
<td>CME Knowledge Assessment (ARS)</td>
</tr>
<tr>
<td>8:00AM - 9:00AM</td>
<td><strong>4. Clinical Trials</strong></td>
</tr>
<tr>
<td>8:00AM - 8:10AM</td>
<td>Update on Australian MCC Clinical Trials</td>
</tr>
<tr>
<td>8:10AM - 8:20AM</td>
<td>AST-008 and TLR9 agonists in Merkel cell carcinoma</td>
</tr>
<tr>
<td>8:20AM - 8:30AM</td>
<td>Randomized Phase II Study of NIVO + IPI vs. NIVO + IPI + SBRT in Metastatic or Recurrent Merkel Cell Carcinoma</td>
</tr>
<tr>
<td>8:30AM - 8:40AM</td>
<td>Ablative Radiation Therapy for Merkel Cell Carcinoma</td>
</tr>
<tr>
<td>8:40AM - 9:00AM</td>
<td>Clinical Trials Discussion - Panel</td>
</tr>
<tr>
<td>9:00AM - 9:15AM</td>
<td>BREAK</td>
</tr>
<tr>
<td>9:15AM - 10:35AM</td>
<td><strong>5. MCC Biology II</strong></td>
</tr>
<tr>
<td>9:15AM - 9:35AM</td>
<td>Transcriptional Responses to Type II Interferon Treatment in Merkel cell carcinoma</td>
</tr>
<tr>
<td>9:35AM - 9:55AM</td>
<td>Can we harness T cells specific for Merkel cell polyomavirus with therapeutic vaccination?</td>
</tr>
<tr>
<td>9:55AM - 10:15AM</td>
<td>MCPyV-specific T cell discovery for adoptive T cell therapy</td>
</tr>
<tr>
<td>10:15AM - 10:35AM</td>
<td>Contribution of Merkel Cell Polyomavirus to Merkel Cell Carcinoma</td>
</tr>
<tr>
<td>10:35AM - 10:45AM</td>
<td>BREAK</td>
</tr>
</tbody>
</table>
### MCC Immunotherapy: Lessons Learnt and Unmet Needs
11:20AM - 11:40AM
Shallender Bhatia, MD

### Treatment Discussion - Panel
11:40AM - 12:00PM
Shallender Bhatia, MD
Sandra D’Angelo, MD
UPENDRA PARVATHANENI, MBBS, FRANZCR
Suzanne Topalian, MD
Alexander van Akkooi, MD, PhD

**LUNCH**
12:00PM - 1:00PM

### Poster Session (non-accredited)
12:05PM - 2:05PM

### Merkel Cell Carcinoma in France: Characteristics of a Cohort of 1300 Patients
2:00PM - 2:12PM
Astrid Blum, MD

**Featured Abstract: Virally mediated mechanisms of HLA class I loss in Merkel cell carcinoma and implications for viral epitope presentation**
2:15PM - 2:30PM
Derrin Keskin, PhD

**3. Abstract Sessions**
2:30PM - 3:42PM

**Abstract: Merkel polyoma virus specific transgenic T cell receptor therapy in PD-1 inhibitor refractory Merkel cell carcinoma**
2:30PM - 2:42PM
Joshua Veatch, MD, PhD

**Abstract: Development of a Merkel polyomavirus-specific T cell receptor analysis tool to guide cancer immunotherapy**
2:42PM - 2:54PM
Saumya Jani, B.S.

**Abstract: MCPyV ALT0 is silenced in virus-positive Merkel cell carcinoma and suppresses tumorigenesis**
2:54PM - 3:06PM
Nick Salisbury, PhD

**Abstract: Real-world assessment of ipilimumab plus nivolumab in anti-PD-L1/PD-1 - refractory Merkel 1 Cell Carcinoma**
3:06PM - 3:18PM
Sophia Shalhout, PhD

**Abstract: Impact of duration of immunotherapy on clinical outcomes in advanced Merkel cell carcinoma patients responding to first-line immunotherapy**
3:18PM - 3:30PM
Lisa Tachiki, MD

**Abstract: The paranuclear dot in Merkel cell carcinoma, how does it form and what does it do?**
3:30PM - 3:42PM
Natasha Hill, PhD

**CME Knowledge Assessment (ARS)**
3:45PM - 3:55PM

### Closing Remarks
3:55PM - 4:05PM
Paul Nghiem, MD, PhD

**ADJOURN**
4:05PM - 4:10PM

### MCC Symposium Photo
4:10PM - 4:20PM

### Symposium Reception
6:00PM - 8:00PM

### 6. MCC Surveillance & Real-World Studies
10:45AM - 12:00PM

**Cross-sectional Imaging In Merkel Cell Carcinoma: Is Less More?**
10:45AM - 11:00AM
Vernon K. Sondak, MD

*Immunotherapy for solid organ transplant recipients with advanced MCC and other skin cancers*
11:00AM - 11:15AM
Evan Lipson, MD

**Diagnostic Yield of Staging Brain MRI in Merkel Cell Carcinoma**
11:15AM - 11:30AM
David Miller, MD, PhD, FAAD

**Real world management of MCC patients in France**
11:30AM - 11:45AM
Mahbab Samimi, MD, PhD

**Avelumab in mMCC: real-world data**
11:45AM - 12:00PM
Margot Tesselaar, MD

**CME Knowledge Assessment (ARS)**
12:00PM - 12:10PM

### 7. Panel Discussions
12:10PM - 3:20PM

**Genomics and Novel Targets - Panel Discussion**
12:50PM - 1:20PM
Kenneth Tsai, MD, PhD
James A. DiCaprio, MD
Isaac Brownell, MD, PhD
Denise Galloway, PhD

**The Optimal Role of Radiation Therapy & Surgery - Panel Discussion**
1:20PM - 1:50PM
UPENDRA PARVATHANENI, MBBS, FRANZCR
Emily Keung, MD

**Socioeconomic and Racial Disparities in MCC - Panel Discussion**
1:50PM - 2:20PM
Abbas Rattani, MD
Mackenzie Martin, BA
Kyle Laurick, MD, Resident Physician (PGY-1)
Ata Moshiri, MD, MPH (Facilitator)

**Duration of Immunotherapy - Panel Discussion**
2:20PM - 2:50PM
Shallender Bhatia, MD
Lisa Tachiki, MD
Lisa Zaba, MD, PhD

**New Therapies on the Horizon - Panel Discussion**
2:50PM - 3:30PM
David Koelle, MD
Paul Nghiem, MD, PhD
Michael Wong, MD, PhD

**Closing Remarks**
3:30PM - 3:35PM
Paul Nghiem, MD, PhD

**ADJOURN**
3:35PM - 3:40PM

Follow UW CME on [Facebook](https://www.facebook.com/uwcmes) and [Twitter](https://twitter.com/uwcme)